Profile
Sector:
HealthcareIndustry:
Medical DevicesCountry:
United StatesIPO:
25 June 2015Website:
http://www.glaukos.comNext earnings report:
02 August 2024Last dividends:
N/ANext dividends:
N/APrice
regular market | 4 min agoDividend
Analysts recommendations
Institutional Ownership
GKOS Latest News
Investors are optimistic about Glaukos' (GKOS) strength in its flagship iStent.
Glaukos (GKOS) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might help the stock continue moving higher in the near term.
ALISO VIEJO, Calif.--(BUSINESS WIRE)--Glaukos Corporation (NYSE: GKOS), an ophthalmic pharmaceutical and medical technology company, today announced that it entered into separate, privately negotiated exchange agreements (the “Exchange Agreements”) with certain holders of its 2.75% Convertible Senior Notes due 2027 (the “Existing Convertible Notes”). Pursuant to these Exchange Agreements, the company agreed, subject to customary closing conditions, to repurchase an aggregate of $230 million pri.
Investors are optimistic about Glaukos' (GKOS) strength in its flagship iStent.
Glaukos (GKOS) continues to benefit from a robust product portfolio and favorable clinical trial results.
ALISO VIEJO, Calif.--(BUSINESS WIRE)--Glaukos Corporation (NYSE: GKOS), an ophthalmic pharmaceutical and medical technology company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, today announced that its management is scheduled to participate in the following upcoming investor conferences: William Blair 44th Annual Growth Stock Conference on Wednesday, June 5, 2024, at 1:40 p.m. ET in Chicago, IL Truist MedTech Conference on Tuesday, June 18, 2.
Investors are confident in Glaukos' (GKOS) strong position with its flagship iStent product.
Glaukos' (GKOS) Q1 2024 financial results demonstrate revenue growth but fall short of the Zacks consensus estimate for earnings. Concerns are raised over the operating loss.
Glaukos Corporation (NYSE:GKOS) Q1 2024 Earnings Conference Call on May 1, 2024 at 4:30 PM ET. Company executives present include Chris Lewis, Tom Burns, Joe Gilliam, and Alex Thurman. Various analysts and investors are also participating in the call. Welcome to Glaukos Corporation's First Quarter 2024 Financial Results Conference Call. The company's press release and quarterly summary document can be found at www.glaukos.com.
Glaukos (GKOS) reported a quarterly loss of $0.70 per share, missing the Zacks Consensus Estimate of $0.58. This is higher than the loss of $0.59 per share reported in the same period last year.
What type of business is Glaukos?
Glaukos Corporation is a company specializing in ophthalmic medical technologies and pharmaceuticals, focusing on developing new methods for treating glaucoma, corneal diseases, and retinal diseases. The corporation was founded in 1998, with its headquarters in San Clemente, California. The company has developed micro-invasive glaucoma surgery (MIGS) as an alternative to traditional glaucoma treatment, and in 2012 launched its first MIGS device for sale. They have also developed a patented bioactivated pharmaceutical therapy for treating corneal disorders. Glaukos Corporation is involved in developing lines of surgical devices, pharmaceutical therapy, and implantable biosensors for treating the progression of glaucoma, corneal diseases such as keratoconus, dry eye, and a variety of other conditions.
What sector is Glaukos in?
Glaukos is in the Healthcare sector
What industry is Glaukos in?
Glaukos is in the Medical Devices industry
What country is Glaukos from?
Glaukos is headquartered in United States
When did Glaukos go public?
Glaukos initial public offering (IPO) was on 25 June 2015
What is Glaukos website?
https://www.glaukos.com
Is Glaukos in the S&P 500?
No, Glaukos is not included in the S&P 500 index
Is Glaukos in the NASDAQ 100?
No, Glaukos is not included in the NASDAQ 100 index
Is Glaukos in the Dow Jones?
No, Glaukos is not included in the Dow Jones index
When does Glaukos report earnings?
The next expected earnings date for Glaukos is 02 August 2024